Internal Medicine, Medical Oncology · Frederick, MD
NPI
1013931526
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1562 Opossumtown Pike
Frederick, MD, 21702
Phone (301) 662-8477
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.0M
237,875 services
Medicare patients, 2024
762
Average age 75
Drug cost, 2024
$1.5M
734 prescriptions
Company payments, 2025
$157
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Patrick J Mansky was code J9271 (injection, pembrolizumab, 1 mg), 17,800 times for 26 patients. In total Patrick J Mansky billed 237,875 services in 155 codes, and Medicare paid $4.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-05-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 17,800 | 26 | $41.83 | $745K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 16,800 | 40 | $0.11 | $1,857 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 12,050 | 19 | $0.05 | $653 |
| J1756 Injection, iron sucrose, 1 mg | Office | 11,300 | 25 | $0.18 | $2,017 |
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 8,700 | 12 | $17.32 | $151K |
| J0897 Injection, denosumab, 1 mg | Office | 7,980 | 68 | $20.14 | $161K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 7,650 | 12 | $0.28 | $2,115 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 3,760 | 15 | $34.31 | $129K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,298 | 96 | $0.09 | $283 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 3,130 | 100 | $0.12 | $367 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 996 | 24 | $3.41 | $3,399 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 573 | 11 | $0.18 | $102 |
| J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | Office | 509 | 12 | $2.65 | $1,351 |
| J9190 Injection, fluorouracil, 500 mg | Office | 473 | 27 | $2.28 | $1,080 |
| 96375 Injection Administration | Office | 466 | 119 | $12.24 | $5,706 |
By year: 2022 $2.8M for 184,043 services; 2023 $3.6M for 219,095 services; 2024 $4.0M for 237,875 services.
Medicare prescription drug claims, 2024
In 2024, the drug Patrick J Mansky prescribed most often to Medicare patients was Eliquis (Apixaban), with 116 prescriptions and refills. In total Patrick J Mansky wrote 734 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 116 | 201 | 24 | $116K |
| Letrozole Generic | 79 | 205 | 22 | $2,261 |
| Xarelto Rivaroxaban | 66 | 136 | 16 | $73K |
| Ondansetron Odt Ondansetron | 28 | 28 | 16 | $368 |
| Exemestane Generic | 26 | 62 | Under 11 | $5,134 |
| Anastrozole Generic | 26 | 78 | Under 11 | $950 |
| Hydroxyurea Generic | 26 | 56 | Under 11 | $413 |
| Gabapentin Generic | 25 | 25 | Under 11 | $109 |
| Prednisone Generic | 22 | 30 | Under 11 | $179 |
| Enoxaparin Sodium Generic | 22 | 24 | Under 11 | $7,205 |
| Imatinib Mesylate Generic | 20 | 20 | Under 11 | $68K |
| Abiraterone Acetate Generic | 19 | 19 | Under 11 | $31K |
| Folic Acid Generic | 18 | 22 | Under 11 | $81.18 |
| Dexamethasone Generic | 15 | 22 | Under 11 | $294 |
| Verzenio Abemaciclib | 13 | 13 | Under 11 | $200K |
Brand drugs: - claims; generic drugs: 479 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Patrick J Mansky $157 ($157 in general payments such as food, travel and fees) from 4 companies. The largest payer was Novartis Pharmaceuticals Corporation with $78.38.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.